AbstractObjectivesThis study investigated outcomes in patients with cardiogenic shock and severe renal dysfunction treated with ventricular assist devices (VAD) as a bridge to cardiac transplantation.BackgroundPrevious reports have documented poor survival in patients with cardiogenic shock and severe renal dysfunction treated with VAD.MethodsWe surveyed 215 consecutive patients who received a VAD from 1992 to 2000 and selected patients who had a serum creatinine ≥3.0 mg/dl at the time of VAD placement. Demographic, laboratory, and clinical outcome data were collected.ResultsEighteen patients met the inclusion criteria. Mean serum creatinine at the time of VAD placement was 4.0 ± 0.7 mg/dl (range 3.0 to 5.2 mg/dl). Seven patients required t...
Donors after cardiac death (DCD) could increase the organ pool. Data supports good long-term renal g...
A 60-year-old male patient presented to an outside hospital with severe cardiogenic shock. A triple ...
ObjectivesWe evaluated the efficacy and safety of the percutaneous ventricular assist device (pVAD) ...
AbstractObjectivesThis study investigated outcomes in patients with cardiogenic shock and severe ren...
AbstractObjectiveThis study examines short-term mechanical assist device support for cardiac transpl...
Over the last three years, we have used ventricular assist devices (VAD) in 7 patients. Of these 7, ...
Aims: Renal dysfunction (RD) is a potent risk factor for death in patients with cardiovascular disea...
The use of implantable ventricular assist devices for the treatment of advanced, decompensated heart...
[Abstract] Chronic kidney disease (CKD) is staged on the basis of glomerular filtration rate; genera...
Renal failure after left ventricular assist device (LVAD) implantation occurs either due to worsenin...
ObjectivesThis study sought to determine the relationship between pre-transplant ventricular assist ...
AimMechanical circulatory support is an alternative strategy as a bridge to transplantation for crit...
AbstractObjective: Improving results with ventricular assist devices have led to their wider clinica...
Background: The extracorporeal ventricular assist device (e-VAD) system is designed for left ventric...
AbstractIntroductionShort-term ventricular assist device (VAD) implantation is a life-saving procedu...
Donors after cardiac death (DCD) could increase the organ pool. Data supports good long-term renal g...
A 60-year-old male patient presented to an outside hospital with severe cardiogenic shock. A triple ...
ObjectivesWe evaluated the efficacy and safety of the percutaneous ventricular assist device (pVAD) ...
AbstractObjectivesThis study investigated outcomes in patients with cardiogenic shock and severe ren...
AbstractObjectiveThis study examines short-term mechanical assist device support for cardiac transpl...
Over the last three years, we have used ventricular assist devices (VAD) in 7 patients. Of these 7, ...
Aims: Renal dysfunction (RD) is a potent risk factor for death in patients with cardiovascular disea...
The use of implantable ventricular assist devices for the treatment of advanced, decompensated heart...
[Abstract] Chronic kidney disease (CKD) is staged on the basis of glomerular filtration rate; genera...
Renal failure after left ventricular assist device (LVAD) implantation occurs either due to worsenin...
ObjectivesThis study sought to determine the relationship between pre-transplant ventricular assist ...
AimMechanical circulatory support is an alternative strategy as a bridge to transplantation for crit...
AbstractObjective: Improving results with ventricular assist devices have led to their wider clinica...
Background: The extracorporeal ventricular assist device (e-VAD) system is designed for left ventric...
AbstractIntroductionShort-term ventricular assist device (VAD) implantation is a life-saving procedu...
Donors after cardiac death (DCD) could increase the organ pool. Data supports good long-term renal g...
A 60-year-old male patient presented to an outside hospital with severe cardiogenic shock. A triple ...
ObjectivesWe evaluated the efficacy and safety of the percutaneous ventricular assist device (pVAD) ...